

The prevalence of cannabis use disorders in people who use medicinal cannabis: a systematic review and meta-analysis

Danielle Dawson, Daniel Stjepanovic, Valentina Lorenzetti, Christy Cheung, Wayne Hall, Janni Leung



PII: S0376-8716(24)00184-4

DOI: <https://doi.org/10.1016/j.drugalcdep.2024.111263>

Reference: DAD111263

To appear in: *Drug and Alcohol Dependence*

Received date: 18 December 2023

Revised date: 21 February 2024

Accepted date: 22 February 2024

Please cite this article as: Danielle Dawson, Daniel Stjepanovic, Valentina Lorenzetti, Christy Cheung, Wayne Hall and Janni Leung, The prevalence of cannabis use disorders in people who use medicinal cannabis: a systematic review and meta-analysis, *Drug and Alcohol Dependence*, (2024) doi:<https://doi.org/10.1016/j.drugalcdep.2024.111263>

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2024 Published by Elsevier.

The prevalence of cannabis use disorders in people who use medicinal cannabis: a systematic review and meta-analysis

Full Author names

Danielle Dawson^{1,2}, BPsychSc (Hons), danielle.dawson@uq.edu.au*

Daniel Stjepanovic^{1,2} Research Fellow, d.stjepanovic@uq.edu.au

Valentina Lorenzetti³, Associate Professor, valentina.lorenzetti@acu.edu.au

Christy Cheung^{1,2}, BSc(HBA), christy.cheung@uq.net.au

Wayne Hall², PhD, Emeritus Professor, w.hall@uq.edu.au

Janni Leung^{1,2}, PhD, Research Fellow, j.leung1@uq.edu.au

Affiliation

1. School of Psychology, The University of Queensland, St Lucia QLD 4072, Australia
2. National Centre for Youth Substance Use Research, The University of Queensland, 31 Upland Road, St Lucia QLD 4067, Australia
3. Healthy Brain and Mind Research Centre, School of Behavioural & Health Sciences, Faculty of Health Science, Australian Catholic University, Daniel Mannix Building, Fitzroy, VIC 3065, Australia

***Corresponding author:** Ms Danielle Dawson. The University of Queensland, NCYSUR, 31 Upland Road, St Lucia, QLD 4072, Australia.
danielle.dawson@uq.edu.au, +61733469643

Abstract:

Background:

The prevalence of cannabis use disorders (CUDs) in people who use cannabis recreationally has been estimated at 22%, yet there is a dearth of literature exploring CUDs among people who use medicinal cannabis. We aimed to systematically review the prevalence of CUDs in people who use medicinal cannabis.

Methods:

In our systematic review and meta-analysis, we followed PRISMA guidelines and searched three databases (PsychInfo, Embase and PubMed) to identify studies examining the prevalence of CUDs in people who use medicinal cannabis. Metaanalyses were calculated on the prevalence of CUDs. Prevalence estimates were pooled across different periods (recent use and 6-12 months) using the DSM-IV and DSM-5.

Results:

We conducted a systematic review of 14 eligible publications, assessing the prevalence of CUDs with three diagnostic criteria, providing data for 3681 participants from five different countries. The systematic review demonstrated that demographic factors, mental health problems and the management of chronic pain with medicinal cannabis were associated with an elevated risk of CUDs. A meta-analysis was conducted on the prevalence of CUDs. For individuals using medicinal cannabis in the past 6-12 months, the prevalence of CUDs was 29% (95% CI: 21-38%) as per DSM-5 criteria. Similar prevalence was observed with DSM-IV (24%, CI: 14-38%) for the same period.

Conclusions:

The prevalence of CUDs in people who use medicinal cannabis is substantial and comparable to people who use cannabis for recreational reasons, emphasizing the need for ongoing research to monitor the prevalence of CUDs in people who use medicinal cannabis.

Keywords:

cannabis; Cannabis use disorder; medicinal cannabis; cannabis dependence; Cannabis abuse

1 Introduction

The increase in the use of medicinal cannabis on a global scale has prompted concern about the potential to develop negative consequences associated with its medical use (1–3). Recent literature indicates that over one quarter (27%) of adults in the United States have used cannabis for medicinal reasons (3). More than a dozen nations across the world (e.g., Australia, Canada, United States) have enacted legislation to allow the medical use of cannabis for a variety of medical problems such as chronic pain, anxiety, sleep problems and neurological disorders (4,5). In most countries, only a brief screening process conducted by a physician is typically required to gain access to medical cannabis (6). The monitoring of cannabis use is not usually mandated, and patients are granted the autonomy to select from a diverse range of cannabis products through an administrative entity rather than relying on a traditional prescription-based approach that specifies doses of cannabinoids that will be used (5,7). A matter of considerable concern within the realm of public health is that the regular use of medicinal cannabis (e.g. for chronic pain) may place patients at a heightened risk of cannabis use disorders, which are prevalent (22% [95% CI: 18–26%]) among individuals who engage in recreational cannabis use (3). To date, there is a dearth of literature exploring the prevalence and risk factors for cannabis use disorders among people who use cannabis medicinally.

The diagnostic criteria for cannabis use disorders (CUDs) have evolved over time, as reflected in changes in the Diagnostic and Statistical Manual of Mental Disorders (DSM) editions, and within the International Classification of Diseases (ICD) definitions (8). In the DSM-IV, cannabis abuse and dependence were treated as separate entities, with specific criteria for each. Dependence was characterized by a compulsion to use cannabis, loss of control over use and tolerance (9). The DSM-5 removed the distinction between abuse and dependence, introducing a single diagnosis of CUD that varied in severity from mild to moderate and severe. The DSM-5 criteria encompasses symptoms such as the development of tolerance, withdrawal symptoms, unsuccessful efforts to reduce or control use, and continued use despite known adverse consequences (10,11). The most recent edition of the ICD system, the ICD-11, describes problematic cannabis use as a pattern that leads to significant health, social, or personal problems (12). The broad criteria used in the ICD-11 are less granular than the DSM-5 but captures the essence of problematic cannabis consumption that adversely affects daily life.

Despite medical authorisation, people who use cannabis for medicinal reasons may still develop CUDs (6,13). Over time and increased exposure, these individuals may build a tolerance to the effects of THC, requiring increased doses to achieve the same medicinal effects (14). Escalating use can lead to physical and psychological dependence, where users experience withdrawal symptoms like irritability, insomnia, or restlessness if they reduce or stop using medicinal cannabis (15). Moreover, some patients might find themselves dedicating excessive time to obtaining or using medicinal cannabis, or they may persist in its use despite recognizing its adverse effects on their mental health or social, professional, or personal life (16). It is important to recognize that even within a medical context, the risk of developing CUDs remains, and it is important to track and minimise this risk where possible. In this paper, we aim to conduct the first systematic review of the evidence on the prevalence of CUDs in people who use cannabis for medicinal reasons.

2 Method

2.1 Protocol

The systematic review and meta-analysis was conducted in accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Supporting Information 1), and the protocol was prospectively registered at the International Prospective Register of Systematic Reviews (PROSPERO) with registration ID: CRD42023396332 (17).

2.2 Search strategy and selection criteria

The eligibility criteria were developed based on the framework of the population, exposure, comparison and outcome (PECO) eligibility checklist (Supporting Information 2). Articles that reported human exposure to medicinal cannabis at any level of the population were included. Studies that reported exposure exclusively to recreational cannabis were excluded. If recreational and medicinal cannabis exposure was reported, the study was included. To be included, the study had to report the prevalence (%) of problematic cannabis use, cannabis use disorder, cannabis dependence or cannabis abuse in people who use cannabis for medicinal reasons. We searched PsychInfo, Embase and PubMed for published studies using search terms related to “cannabis use disorder” and “medicinal cannabis” (Supporting Information 3) starting from 2010 to ensure recent literature. The search was performed in March 2023. Google Scholar, hand search, Elicit and other additional searches were performed.

2.3 Selection process

The primary measure was the percentage of those who met the threshold set by the criteria used in each study for problematic cannabis use, CUD, CA or CD (herein ‘Cannabis Use Disorders’), among those who had used cannabis for medicinal reasons.

2.4 Data extraction

Data was extracted by two investigators independently and cross-checked. We extracted data on year of publication, age and gender of participants, how medicinal cannabis exposure was defined (e.g., self-report, possession of medicinal cannabis card), the criteria used for CUDs (e.g., DSM-5), prevalence period, how CUDs were measured (i.e., tool used). We also collected data on the medicinal cannabis products used, route of administration, recreational cannabis use, and other medications used if reported.

2.5 Quality assessment

Two investigators independently assessed the risk of bias for the included studies using the JBI risk-of-bias tool for cross-sectional, cohort and randomised clinical trials (18), with dichotomised scoring for each item. There was a high level of agreement in the assessments between the raters (>90% rating scores across all studies), and consensus was reached for all studies after discussion (Supporting Information 4).

2.6 Data analysis

A random effects meta-analysis were conducted to pool the prevalence estimates extracted. R Studio (version 2023.06.2+561) was used to conduct the meta-analysis. The double arcsine transformation method was used to address variance instability. Cochran’s Q value, as well as I^2 statistics, were used to assess heterogeneity of the study findings. Stratified analyses were conducted by prevalence time frame and diagnostic criteria.

3 Results

The search identified 521 unique records. After title and abstract screening, we included 39 articles for full-text screening. 14 articles were retained for quantitative meta-analyses following full-text screening (see Figure 1).

Figure 1

Study Design

Ten studies were cross-sectional, two were cohort studies and two were randomized clinical trials. Eight of the samples were located in the United States, two were from Australia, two from Canada, one from Israel and one from Germany (see Table 1).

Table 1

Risk of Bias

The quality score for cross-sectional studies was between 6 and 8 out of 10, for cohort studies it was 10 out of 11, and randomised clinical trials were both 11 out of 13. Most of the studies relied on self-

report measures for CUDs. Overall, the studies were of good to very good quality and did not have a high risk of bias (see Supporting Information 4; S7, 9, 11.).

Diagnostic Criteria

Ten studies used the DSM-5 criteria to diagnose CUDs among people who used medicinal cannabis. Of these, three studies administered novel questionnaires based on the DSM-5 criteria during interviews. Three administered self-report novel questionnaires based on the DSM-5 criteria. One study used the Alcohol Use Disorder and Associated Disabilities Interview 5 (AUDADIS-V, 19). Finally, three studies used the self-reported Cannabis Use Disorder Identification Test-Revised (CUDIT-R) to screen for CUDs (20). Three studies used the DSM-IV criteria. Of these, one used a novel self-report questionnaire, one used the AUDASIS-IV (21) and another used a structured clinical interview. Degenhardt et al (2015) used the ICD 10 criteria assessed by the World Health Organization Composite International Diagnostic Interview (WHO CIDI) version 3.0 (22) .

Sample Characteristics

Three studies recruited participants with chronic pain; two of which measured past year prevalence of CUDs and one measured lifetime prevalence (21–23). Two studies recruited participants from medicinal cannabis dispensaries in the US to investigate the past 6-month prevalence of CUDs (14,15). Three studies used national level surveys to assess the past 12-month prevalence of CUDs (16,24,25). One randomised clinical trial assessed numerous time points for CUDs, with 3 months the most protracted (26). A cohort study from the same clinical trial reported a nine month follow up on the rates of CUDs within the same participant pool (13). Another clinical trial reported the 12-month prevalence of CUDs (27). One study recruited participants who were incoming into inpatient treatment for substance use disorders (6) and measured CUDs in the following 3 months. Another two studies recruited veterans and a university sample and measured the 6 month prevalence of CUDs (27,30). None of the studies excluded participants based on any lifetime cannabis past use but three excluded participants who had used on near-daily (27) or daily use in the past 3 months in an attempt to not confound the sample with participants who may already have or be developing CUDs (13,26).

Symptoms of CUD

Of the seven studies which described the frequency of endorsed symptoms, over half reported tolerance to cannabis as the most frequently reported symptom of CUDs (16,21,26,27). Tolerance was defined by either (1) a need for markedly increased amounts of cannabis to achieve intoxication or desired effect; or (2) a markedly diminished effect with continued use of the same amount of cannabis. Withdrawal, as defined as cannabis taken to relieve or avoid withdrawal symptoms, was also frequently endorsed in numerous studies (16,20,22). Other common symptoms endorsed were as follows: 1) cannabis was often taken in larger amounts or over a longer period than was intended; 2) a persistent desire or unsuccessful efforts to cut down or control cannabis use; 3) craving; 4) recurrent cannabis use in situations in which it is physically hazardous; 5) continued use despite knowledge of having a persistent or recurrent physical or psychological problem that is likely to have been caused or exacerbated by cannabis.

Route of Administration and Product Type

Most studies reported that the majority of participants administered cannabis via inhalation (i.e., through joints, bongs and vaporisers). Only one study reported a majority of oral cannabis administration of which 74% was oral dronabinol (21). Mills et al. (2022) found a positive association between inhalation as the route of administration of cannabis and the prevalence of CUDs. Haug et al., (2017) found that inhalation was the most common route of administration and was positively associated with CUDs but noted age differences in the preference of route of administration in which older users preferred oral ingestion, while younger and middle-aged users preferred inhalation (14).

Information on the specific product type (e.g., cannabis plant matter, vaping liquid, capsules) was not collected by most of the included studies. The nature of medicinal cannabis authorisation to use a range of products rather than prescriptions was noted as a limitation for examining which products were used in multiple studies (13,26,27).

Meta-Analysis

We compared the prevalence of CUDs in studies using specific DSM criteria versions and varied prevalence periods. The pooled prevalence of CUDs was 29% (95% CI: 21-38%) as assessed by the

DSM-5 criteria in people who had used medicinal cannabis in the past 6–12-month period ($k = 7$; see Table 3; forrest plots are available in Supporting Information 5). Pooled estimates were similar for studies which used the DSM-IV criteria in the 6-12 months prevalence period, estimated at 24% (CI: 14-38%; $k = 3$). CUDs prevalence in the recent use prevalence period (past 3 months) was 17% (CI: 10-28%) when assessed by DSM-5 criteria ($k = 2$). Pooled estimates across prevalence periods (i.e., recent use and 6-12month) using the DSM-5 criteria yielded similar pooled estimates of CUDs at 25% (CI: 18-33%) in people who have used medicinal cannabis. Degenhardt et al., (2015) was the only study to use the ICD-10 criteria reporting the lifetime prevalence of CUDs at 33% (CI: 27–39%). Estimates of CUDs between the studies varied largely, ostensibly due to heterogeneity in the populations sampled.

Table 2

Narrative Review

There were not enough studies reporting estimates of CUD by severity, frequency of use, age, and gender so meta-analyses were not conducted by these subgroups or moderators. Instead, findings were summarised narratively.

Severity of CUD

Eight studies reported the severity of CUDs, most often within the DSM-5 framework which categorises CUDs as mild, moderate and severe. There was a higher proportion of mild CUD (55-80%) compared to moderate (11 -27%) and severe (0-20%) across studies (see Table 3).

Table 3

Frequency of Use

The frequency of medicinal cannabis use was positively associated with CUDs in some studies. When comparing medicinal to recreational use, one study found that medical cannabis card holders had a higher rate of daily use (64%) than non-card holders (35%; see 27). In another study, people who used cannabis medicinally consumed cannabis more frequently than those who used it recreationally (see 24). In Lin et al., (2016) frequency of use was associated with CUDs, and people who used medical cannabis were 3-times more likely to use cannabis daily (33%) than people who used recreationally (11%).

Age

Rubin-Kahana. et al (2022) found that people who were younger ($Range=18-29$ years) were more likely to develop CUDs when using medicinal cannabis than older people ($Range=30-44$; $p < .05$). Haug et al., (2017) also found that being younger was a significant predictor of problematic medicinal cannabis use ($\chi^2=15.91$, $p < .001$). This was moderated by age of first regular use such that an earlier age of regular use was associated with more problematic use in the younger users, but not among older users ($F=7.62$, $p < .001$). One study reported that males were more likely to develop CUDs than females when using medicinal cannabis (Cohen's $d=0.12$, $p < .05$, see 23).

Mental Health

Of the included studies which investigated medicinal cannabis use among individuals with depression, these concluded that it may place them at a higher risk of developing CUDs (13,23,29). Particular symptoms of depression (i.e., heightened dysphoria and lassitude) were associated with a greater risk of CUDs (15). Rubin-Kahana et al., (2022) found participants with PTSD, mood disorders, psychotic disorders, or personality disorders were more likely to develop CUDs compared to other health conditions. Broad-spectrum measures of psychological health in people using medicinal cannabis were also negatively associated with a greater risk of CUDs, such that poorer psychological health and worsened mental health were associated with higher rates of CUDs (16,22,24). Moreover, individuals experiencing SUDs while using medicinal cannabis were found to be particularly vulnerable to developing CUDs (6).

Chronic Pain

The relationship between chronic pain and CUDs in people who used medicinal cannabis was assessed in numerous studies. Adults using medicinal cannabis for pain may be at higher risk of developing

CUDs, possibly without a clinically significant reduction in symptoms (31,32). Individuals using medicinal cannabis for chronic pain who developed CUDs were more likely to have greater symptoms of pain which impact daily functioning in some studies (22).

4 Discussion

The current paper is the first systematic review and meta-analysis to estimate the prevalence and symptoms of cannabis use disorders in people who use medicinal cannabis. In people who use cannabis for medicinal reasons, 25% (CI: 18-33%) were estimated to have a CUD when including all prevalence periods using the DSM-5. Our estimate of 25% is marginally higher than the 22% (CI: 18-26%) from a recent meta-analysis on the prevalence of CUDs among people who used cannabis recreationally, which found daily or weekly use and younger age as significant risk factors but with overlapping confidence intervals (32).

As in Leung et al., (2021), our narrative review suggests that the risk of CUDs may be higher in people who use medicinal cannabis frequently, use greater quantities of medicinal cannabis daily and are more likely to use medicinal cannabis via inhalation. Demographic predictors of CUDs when using medicinal cannabis were being younger in age and male. Physical and mental health conditions as associated risk factors were also identified (e.g., chronic pain) but can be complex to understand, given that some patients utilise medical cannabis for these health conditions. Cooke et al., (2023) posited that increased symptoms of pain, which impact daily functioning, led to more frequent medicinal cannabis use and consequently the development of CUDs. They noted that it is unlikely that cannabis use directly worsened pain. Instead, it is proposed that individuals experiencing higher levels of pain turn to medicinal cannabis more frequently as a pain management strategy. The link between greater cannabis use and greater pain might indicate that cannabis is not effectively addressing pain symptoms but may increase the risk of CUDs for those using cannabis for chronic pain (27). The development of a CUD may, in turn, impair their ability to manage their pain and the demands of everyday life (27).

The present review found withdrawal and tolerance to be two of the most frequently reported criteria across the included studies. Two included studies examined the effect of removing the tolerance and withdrawal criteria and recalculating the prevalence of CUDs in the sample. For Mills et al. (2022) and Bialas et al. (2022), this resulted in a reduction in the number of CUDs identified in the study (25% versus 32%; 14% versus 29%, respectively). The validity, specificity and sensitivity of the adjusted criteria were not tested. The rationale for removing these criteria stems from the medicinal authorisation of cannabis, with some researchers claiming withdrawal and tolerance should be removed when assessing medicinal use (as in Opiate Use Disorder; OUD) (21) and others suggesting the criteria should be changed to CUD-Cannabis for Therapeutic Purposes (CTP) to adjust for medicinal use (33). The DSM-5 OUD criteria states that tolerance and withdrawal symptoms are not considered applicable for individuals utilising opioids under appropriate medical oversight.

Conversely, no such exemption is provided in the DSM-5 diagnostic code for CUD and does not incorporate provisions for appropriate medical supervision. Recent research has highlighted that while tolerance and withdrawal may be removed for prescription medications within appropriate medical treatment, medicinal cannabis differs in being acquired through a recommendation rather than a standard prescription. The unique regulatory system means physicians recommending cannabis lack control over the dosages, potencies, frequencies and even products that their patients use in some jurisdictions, often without specific clinical guidelines (27). Other researchers have questioned the rationale for removing withdrawal and tolerance from the criteria because these are symptoms that are important to track. Some have also highlighted that it was the argument that tolerance and withdrawal were 'expected' in people who used opioid medications long-term that led to the severe underestimation of the harms and prevalence of opioid use disorder in patients using opioids for medical purposes (6). Motives for use may be an essential factor to consider in the context of CUDs. Still, many of the included studies did not examine these comprehensively and warrants future research (30).

Dual use motives of cannabis (i.e., medicinal versus recreational) complicate the estimation of the prevalence of CUDs in people who use medicinal cannabis. The definition of 'medicinal' or 'recreational' use is often obscured by the flexible cannabis authorisation processes, which do not adhere to the traditional approach of prescribing specific drugs and dosages. Previous studies have shown that many people who used cannabis self-reported dual use motives (34). Within the reviewed literature, there were various strategies employed to measure the recreational use of medicinal cannabis products or the use of recreational cannabis alongside medicinal cannabis. Bonn-Miller et al., (2014)

and Haug et al., (2017) used a comprehensive cannabis motives questionnaire to delineate medicinal from recreational motives (35). In their sample taken from a medicinal cannabis dispensary, Bonn-Miller et al., (2014) found that using medicinal cannabis for coping, boredom, enjoyment, celebration, to alter perception, availability and experimentation was associated with heightened cannabis use problems; all motives which may reflect recreational cannabis use. In a similar population, Haug et al. (2017) found that coping motives significantly predicted problematic cannabis use. However, all the participants in this study were classified as medicinal cannabis patients because they had a medicinal cannabis authorisation.

Another study by Bialas et al., (2022) reported recreational use of cannabis by 16% of the sample, with one in five of those participants reporting the use of recreational cannabis up until the initiation of medicinal cannabis. Other included studies utilised self-report questions to disentangle medicinal use from recreational use, and others such as Mills et al., (2022), allowed participants to respond to the study regardless of whether they were prescribed medicinal cannabis but simply if they self-identified as using cannabis medicinally. There is a serious question here of how researchers, clinicians and public health agencies are to distinguish medicinal cannabis patients when varied proportions also use cannabis recreationally whilst authorised for medicinal use and others claim to be using cannabis medicinally without authorisation. There is no simple biological approach for separating potential 'recreational use misuse' whilst an individual is approved and using medicinal cannabis. There arises a further concern regarding potential research participants who might not genuinely represent medicinal patients, leading to what can be termed "trojan horse" participation. Such participants might not provide meaningful data, especially if their reasons for cannabis use diverge from their claim to be using medically (5). The current review highlights the difficulty in delineating recreational and medicinal cannabis users and emphasises both the need for a valid methodology to separate use motives, or the consistent use of reliable tools in research to monitor motives of cannabis use when prescribed medicinally.

The variance in the methodologies and design of the studies is a major limitation within this review. Estimates using different measures of different diagnostic criteria may be too disparate to pool. We possessed restricted statistical capability to discern the impacts of additional potential moderators. Further, the preponderance of our estimates originated from predominantly cross-sectional studies employing self-reported measures which are susceptible to recall bias and social desirability. Optimally, our inclusion criteria would have been limited to longitudinal cohort studies that began before the initiation of both recreational and medicinal cannabis use and tracked the emergence of CUDs over time. However, to the best of our knowledge, only one study on medicinal cannabis use has partially utilised this approach to date (see 26).

Given that this review is the first of its kind, further research should be aimed at monitoring the population-level prevalence of CUDs in people who use medicinal cannabis, particularly in the face of growing liberalisation and accessibility. The review also highlights the need for public health messaging on the adverse effects of using cannabis for medicinal reasons, irrespective of whether its self-prescribed or authorised by a medical professional, as these effects may be largely unknown to consumers. Additionally, this review underscores the significance for researchers and clinicians to measure recreational use in people who use medical cannabis, highlighting the necessity for enhanced measures to systematically monitor motives associated with medicinal and recreational cannabis use.

5 Conclusion

The current meta-analysis estimates that the prevalence of CUDs in people who use medicinal cannabis is 25% (CI: 18-33%). Frequency of cannabis use, and certain demographics such as younger age and male gender appear to increase risk, as they do in recreational cannabis users. Individuals with mental health problems, especially those using cannabis for depression and SUDs, may be at elevated risk. Chronic pain management with medicinal cannabis may increase the risk of CUDs. The study highlights challenges in distinguishing between recreational and medicinal use and the difficulty this poses for cannabis research in both contexts given the growing liberalisation of cannabis policies. As medicinal cannabis popularity grows, there is a need for ongoing research to monitor CUDs prevalence in people who use medicinal cannabis.

References

1. Gliksberg O, Kushnir T, Sznitman SR, Lev-Ran S, Brill S, Amit BH, et al. Negative experiences of patients using medicinal cannabis: A systematic review of qualitative studies. *Journal of Clinical Nursing*. 2023 Sep;32(17–18):5607–18.
2. Potenza MN, Bunt G, Khalsa JH. Addiction Medicine Physicians and Medicinal Cannabinoids. *JAMA Psychiatry*. 2023 Jul 1;80(7):659.
3. Leung J, Chan G, Stjepanović D, Chung JYC, Hall W, Hammond D. Prevalence and self-reported reasons of cannabis use for medical purposes in USA and Canada. *Psychopharmacology*. 2022 May;239(5):1509–19.
4. European Monitoring Centre for Drugs and Drug Addiction. Cannabis laws in Europe: questions and answers for policymaking. [Internet]. LU: Publications Office; 2023 [cited 2023 Oct 20]. Available from: <https://data.europa.eu/doi/10.2810/151113>
5. Graham M, Chiu V, Stjepanović D, Hall W. A provisional evaluation of Australia's medical cannabis program. *International Journal of Drug Policy*. 2023 Dec;122:104210.
6. Gendy M, Taisir R, Sousa S, Costello J, Rush B, Busse JW, et al. Prevalence of cannabis use disorder among individuals using medical cannabis at admission to inpatient treatment for substance use disorders. *Addictive Behaviors*. 2023 Jul;142:107667.
7. Hallinan CM, Bonomo YA. The Rise and Rise of Medicinal Cannabis, What Now? Medicinal Cannabis Prescribing in Australia 2017–2022. *IJERPH*. 2022 Aug 10;19(16):9853.
8. Connor JP, Stjepanović D, Le Foll B, Hoch E, Budney AJ, Hall WD. Cannabis use and cannabis use disorder. *Nat Rev Dis Primers*. 2021 Feb 25;7(1):16.
9. American Psychiatric Association, editor. Diagnostic and statistical manual of mental disorders: DSM-5-TR. Fifth edition, text revision. Washington, DC: American Psychiatric Association Publishing; 2022. 1 p.
10. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders [Internet]. Fifth Edition. American Psychiatric Association; 2013 [cited 2023 Oct 23]. Available from: <https://psychiatryonline.org/doi/book/10.1176/appi.books.9780890425596>
11. American Psychiatric Association, American Psychiatric Association, editors. Diagnostic and statistical manual of mental disorders: DSM-IV-TR. 4th ed., text revision. Washington, DC: American Psychiatric Association; 2000. 943 p.
12. World Health Organization (WHO). International Classification of Diseases, Eleventh Revision (ICD-11) [Internet]. 2019. Available from: <http://id.who.int/icd/entity/1913137404>
13. Gilman JM, Potter K, Schuster RM, Hoepfner BB, Eden Evins A. Cannabis use for medical symptoms: Patterns over the first year of use. *Addictive Behaviors*. 2023 Sep;144:107719.
14. Haug NA, Padula CB, Sottile JE, Vandrey R, Heinz AJ, Bonn-Miller MO. Cannabis use patterns and motives: A comparison of younger, middle-aged, and older medical cannabis dispensary patients. *Addictive Behaviors*. 2017 Sep;72:14–20.
15. Bonn-Miller MO, Boden MT, Bucossi MM, Babson KA. Self-reported cannabis use characteristics, patterns and helpfulness among medical cannabis users. *The American Journal of Drug and Alcohol Abuse*. 2014 Jan 1;40(1):23–30.

16. Mills L, Lintzeris N, O'Malley M, Arnold JC, McGregor IS. Prevalence and correlates of cannabis use disorder among Australians using cannabis products to treat a medical condition. *Drug and Alcohol Review*. 2022 Jul;41(5):1095–108.
17. PROSPERO [Internet]. Available from: https://www.crd.york.ac.uk/prospéro/display_record.php?ID=CRD42023396332
18. Aromataris E, Munn Z. Chapter 7: Systematic reviews of etiology and risk. In: *JB Manual for Evidence Synthesis* [Internet]. JBI; 2020. Available from: <https://synthesismanual.jbi.global>
19. Grant B, Hasin D. The Alcohol Use Disorder and Associated Disabilities Interview Schedule Diagnostic and Statistical Manual of Mental Disorders-Fourth Edition Version (AUDADIS-IV). Bethesda, MD: National Institute on Alcohol Abuse and Alcoholism; 2001.
20. Adamson SJ, Kay-Lambkin FJ, Baker AL, Lewin TJ, Thornton L, Kelly BJ, et al. An improved brief measure of cannabis misuse: The Cannabis Use Disorders Identification Test-Revised (CUDIT-R)☆. *Drug and Alcohol Dependence*. 2010 Jul 1;110(1–2):137–43.
21. Bialas P, Böttge-Wolpers C, Fitzcharles MA, Gottschling S, Konietzke D, Juckenhöfel S, et al. Cannabis use disorder in patients with chronic pain: overestimation and underestimation in a cross-sectional observational study in 3 German pain management centres. *Pain*. 2023 Jun;164(6):1303–11.
22. Degenhardt L, Lintzeris N, Campbell G, Bruno R, Cohen M, Farrell M, et al. Experience of adjunctive cannabis use for chronic non-cancer pain: Findings from the Pain and Opioids IN Treatment (POINT) study. *Drug and Alcohol Dependence*. 2015 Feb;147:144–50.
23. Feingold D, Goor-Aryeh I, Bril S, Delayahu Y, Lev-Ran S. Problematic Use of Prescription Opioids and Medicinal Cannabis Among Patients Suffering from Chronic Pain. *Pain Med*. 2016 Jun 26;pnw134.
24. Rubin-Kahana DS, Hassan AN, Sanches M, Le Foll B. Medical Cannabis and Past-Year Cannabis Use Disorder Among Adult Recreational Users in the United States: Results From a Nationally Representative Sample. *Front Psychiatry*. 2022 Apr 1;13:836908.
25. Lin LA, Ilgen MA, Jannausch M, Bohnert KM. Comparing adults who use cannabis medically with those who use recreationally: Results from a national sample. *Addictive Behaviors*. 2016 Oct;61:99–103.
26. Gilman JM, Schuster RM, Potter KW, Schmitt W, Wheeler G, Pachas GN, et al. Effect of Medical Marijuana Card Ownership on Pain, Insomnia, and Affective Disorder Symptoms in Adults: A Randomized Clinical Trial. *JAMA Netw Open*. 2022 Mar 18;5(3):e222106.
27. Cooke ME, Potter KW, Jashinski J, Pascale M, Schuster RM, Tervo-Clemmens B, et al. Development of cannabis use disorder in medical cannabis users: A 9-month follow-up of a randomized clinical trial testing effects of medical cannabis card ownership. *Front Psychiatry*. 2023 Mar 7;14:1083334.
28. Myers MG, Ganoczy D, Walters HM, Pfeiffer PN, Ilgen MA, Bohnert KM. Assessing the diagnostic utility of the Cannabis Use Disorder Identification Test – Revised (CUDIT-R) among veterans with medical and non-medical cannabis use. *Drug and Alcohol Dependence*. 2023 Jun;247:109876.
29. Smith JM, Mader J, Szeto ACH, Arria AM, Winters KC, Wilkes TCR. Cannabis Use for Medicinal Purposes among Canadian University Students. *Can J Psychiatry*. 2019 May;64(5):351–5.
30. Hasin DS, Wall MM, Alschuler DM, Mannes ZL, Malte C, Olfson M, et al. Chronic pain, cannabis legalisation, and cannabis use disorder among patients in the US Veterans Health Administration

- system, 2005 to 2019: a repeated, cross-sectional study. *The Lancet Psychiatry*. 2023 Nov;10(11):877–86.
31. Gilman J. A potential downside of cannabis legalisation for older adults with pain. *The Lancet Psychiatry*. 2023 Nov;10(11):823–4.
 32. Leung J, Chan GCK, Hides L, Hall WD. What is the prevalence and risk of cannabis use disorders among people who use cannabis? a systematic review and meta-analysis. *Addictive Behaviors*. 2020 Oct;109:106479.
 33. Chung T, Steinberg ML, Bridgeman MB. Recommendation for Cannabis Use Disorder Diagnosis in a Context of Cannabis for Therapeutic Purposes. *JAMA Psychiatry*. 2023 May 1;80(5):409.
 34. Leung J, Lim CCW, Chiu V, Chung J, Mekonen T, Dawson D, et al. Prevalence and correlates of cannabis use for medicinal reasons – An Australian cross-sectional study. *Addictive Behaviors Reports*. 2022 Jun;15:100436.
 35. Lee CM, Neighbors C, Hendershot CS, Grossbard JR. Development and Preliminary Validation of a Comprehensive Marijuana Motives Questionnaire. *J Stud Alcohol Drugs*. 2009 Mar;70(2):279–87.

Figures & Tables

Figure 1. PRISMA Flowchart




TABLE 1. Study characteristics of the prevalence of cannabis use disorders in people who use medicinal cannabis: a systematic review and meta-analysis

First Author (year)	Country, setting (sample size)	Female	Mean age (SD)	Design	Criteria (diagnostic tool)	Any CUDs (% [95% CI])		
						Lifetime	6 - 12 months	3 months
Bialas (2023) ⁽²¹⁾	Germany, pain service (N=187)	67%	54.4 (--)	Cs	DSM-5 (11 item)	--	29% [23- 36%]	--
Bonn-Miller (2014) ⁽¹⁵⁾	USA, medicinal cannabis dispensary (N=217)	27%	41.2 (14.9)	Cs	DSM-IV (Structured Clinical Interview; CUDIT- R)	--	38% [31- 44%]	--
Cooke (2023) ⁽²⁷⁾	USA, clinical trial setting (N=163)	68%	37.3 (14.4)	RCT	DSM-5 (Structured Clinical Interview; 11 item;)	--	12% [7-17%]	--
Degenhardt (2015) ⁽²²⁾	Australia, pain service (N=237)	38%	48.7 (10.1)	Cohort	ICD-10 (WHO CIDI)	33% [27- 39%]	--	--
Feingold (2016) ⁽²³⁾	Israel, pain service (N=406)	44%	-	Cs	DSM-IV (AUDADIS-IV)	--	21% [17- 25%]	--
Gendy (2023) ⁽⁶⁾	Canada, substance use inpatient service (N=53)	32%	41.3 (10.7)	Cs	DSM-5 (9 item)	--	--	28% [17- 41%]
Gilman (2022) ⁽²⁶⁾	USA, clinical trial setting (N = 105)	72%	37.9 (14.3)	RCT	DSM-5 (11 item)	--	--	10% [5- 17%]
Gilman (2023) ⁽²⁷⁾	USA, clinical trial setting (N=149)	69%	37.5 (14.6)	Cohort	DSM-5 (11 item)	--	13% [8-19%]	--
Haug (2017) ⁽¹⁴⁾	USA, medicinal cannabis dispensary (N=217)	24%	41.2 (14.9)	Cs	DSM-5 (CUDIT- R)	--	35% [29- 42%]	--
Lin (2016) ⁽²⁵⁾	USA, national survey (N=336)	46%	-	Cs	DSM-IV (22 item)	--	14% [10- 18%]	--
Mills (2022) ⁽¹⁶⁾	Australia, national survey (N=905)	43%	44.4 (13.25)	Cs	DSM-5 (11 item)	--	32% [29- 35%]	--
Myers (2023) ⁽²⁸⁾	USA, veterans medical service (N=104)	10%	53.0 (14.7)	Cs	DSM-5 (CUDIT- R)	--	47% [38- 57%]	--

Rubin-Kahana (2022) ⁽²⁴⁾	USA, national surveys (N=362)	36%	39.9 (0.98)	Cs	DSM-5 (AUDADIS-V)	--	47% [42-52%]	--
Smith (2019) ⁽²⁹⁾	Canada, university (N=240)	57%	23.2 (5.2)	Cs	DSM-5 (CUDIT-R)	--	14% [10-19%]	--

Abbreviations:

Cs, cross-sectional; RCT, randomised clinical trial.

22 item - 22 item CUD questionnaire in National Survey on Drug Use and Health 2013

11 item – Novel 11 item questionnaire based on DSM-5 CUD criteria

9 item - Novel 9 item questionnaire based on DSM-5 CUD criteria

AUDADIS – IV - Alcohol Use Disorder and Associated Disabilities Interview Schedule 4

AUDADIS-V – Alcohol Use Disorder and Associated Disabilities Interview Schedule 5

CUDIT R – Cannabis Use Disorder Identification Test (Revised)

- not reported, -- not measured

TABLE 2. Meta-analysis results

	DSM-IV			DSM-5			ICD-10		
	Pooled	(95% CI)	<i>k</i>	Pooled	(95%CI)	<i>k</i>	Observed	(95% CI)	<i>k</i>
Lifetime	-	-	-	0.25	(0.18,0.33)	10	33%	(26.8–38.8)	1*
Recent use (3-month)	-	-	-	0.17	(0.06,0.42)	2	-	-	-
6-12month	0.24	(0.12, 0.37)	3	0.29	(0.21,0.38)	7	-	-	-

Note. – indicates no data for analyses

* meta-analysis not run

TABLE 3. The severities of cannabis use disorders among people with cannabis use disorder

First Author	Year	DSM-5 % (n of Total Cannabis Use Disorders) [95% CI]		
		Mild	Moderate	Severe
Bialas (21)	2023	76% (41) [61-91%]	19% (10) [11-30%]	6% (3) [2-12%]
Cooke (27)	2023	79% (15) [61-94%]	11% (2) [2-20%]	11% (2) [2-20%]
Gendy (6)	2023	60% (9) [37-84%]	20% (3) [9-43%]	20% (3) [9-43%]
Gilman (26)	2022	80% (8) [54-99%]	20% (2) [13-37%]	0% (0) [0-0%]
Gilman (27)	2023	79% (15) [61-94%]	11% (2) [2-20%]	11% (2) [2-20%]
Mills (16)	2022	60% (173) [57-63%]	21% (62) [18-24%]	19% (55) [16-23%]
Myers (28)	2022	73% (40) [64-82%]	24% (13) [14-39%]	7% (4) [1-8%]
Rubin-Kahana (24)	2022	55% (95) [48-62%]	27% (46) [21-33%]	18% (32) [10-26%]

Contributors

Ms Danielle Dawson - Conceptualization, Methodology, Data curation, Formal Analysis, Writing original draft, Validation, Writing - review and editing, Visualization.

Dr Daniel Stjepanovic - Conceptualization, Methodology, Project Administration, Supervision, Resources.

Associate Professor Valentina Lorenzetti - Resources, Supervision, Writing - review and editing.

Ms Christy Cheung - Data curation, Validation, Writing - review and editing, Visualization.

Professor Wayne Hall - Conceptualization, Methodology, Supervision, Resources.

Associate Professor Janni Leung - Conceptualization, Methodology, Formal Analysis, Project Administration, Resources, Supervision.

Conflict of Interest

The authors report no conflicts of interest.

Acknowledgement

National Centre for Youth Substance Use Research (NCYSUR) is supported by Commonwealth funding from the Australian Government provided under the Drug and Alcohol Program. JL acknowledges support from the National Health and Medical Research Council (NHMRC) Fellowship and The University of Queensland Developmental Fellowship. DD acknowledges support from the Research Training Scholarship funded by the University of Queensland. VL was supported by a National Health and Medical Research Council (NHMRC) Fellowship and Al and Val Rosenstraus Research Fellowship. The funding sources had no role in the design of this study and did not have any role during its execution, analyses, interpretation of the data, or decision to submit results for publication.

Research support:

This research received no external financial or non-financial support

Relationships:

There are no additional relationships to disclose

Patents and Intellectual Property:

There are no patents to disclose

Other Activities:

There are no additional activities to disclose

Highlights

- The prevalence of cannabis use disorder in people who use medicinal cannabis is estimated at 25% and is comparable to the rates observed in recreational use
- When using cannabis for medicinal reasons, the risks associated with cannabis use disorder are higher when used to treat mental health problems, pain and substance use disorders
- The results emphasize the need for ongoing research to monitor the prevalence of cannabis use disorder in people who use medicinal cannabis.